Tilray Beats a Path to Scale: HEXO Acquisition Joins the Portfolio as Q3 Inches into Positive EBITDA

Overview: A corrective press release and a strategic pivot

Tilray Brands, Inc. (ticker: TLRY) issued a corrected release detailing its fiscal third quarter results for the quarter ended February 28, 2023, and announcing the planned acquisition of HEXO Corp. The correction underscores the typical post-release scrub—missing line items—while the core message emphasizes enduring profitability and a tilt toward scale in Canada through the HEXO transaction.

Key takeaway: the company did not publish an immediate EPS figure in this release and instead highlights Adjusted EBITDA as the near-term profitability metric. That choice shapes how investors form the EPS consensus and earnings surprise expectations ahead of customary quarterly disclosures, while the narrative centers on cash generation and strategic expansion.

Financial Highlights: Revenue steady, margins and cash signal resilience

• Net revenue: $145.6 million versus $144.1 million in the prior quarter; on a constant currency basis, $154.2 million in Q3 2023, up 2% year over year.
• Distribution revenue: $65.4 million, up 5% from the prior year; on a constant currency basis, $70.1 million (up 12%).
• Gross profit (loss) and margins: gross profit $(11.7) million; adjusted gross profit $44.3 million; gross margin negative 8%, adjusted gross margin 30% (up from 26% year-ago).
• Adjusted cannabis gross profit: $22.2 million; adjusted gross margin 47% (vs 33% prior year).
• Cost discipline: $22 million in annualized run-rate savings realized (and $12 million in actual cost savings) under a $30 million plan; total annualized cash cost-savings since the Tilray-Aphria transaction reach $122 million.
• Adjusted EBITDA: $14.0 million; 16th consecutive quarter of positive adjusted EBITDA; revenue forecast guidance suggests continued earnings trajectory with adjusted EBITDA guidance of $60–$66 million for the full year, a greater-than-30% improvement year-over-year.
• Liquidity: cash and marketable securities of $408.3 million.
• Free cash flow: reiterates expectation for positive free cash flow from operating segments in fiscal 2023.
• Non-cash impairment note: recorded a non-cash $1.1 billion net asset reduction stemming from higher interest rates and a decline in market capitalization; management notes this does not impact debt covenants, cash flows, or liquidity.

The HEXO Acquisition: A Canadian expansion with stock-based consideration

Tilray unveiled a definitive agreement to acquire HEXO Corp. for roughly US$56 million, to be satisfied through the issuance of 0.4352 Tilray common shares for each outstanding HEXO share. The deal is structured as an arrangement under Canadian law, building on an existing strategic alliance and designed to bolster Tilray’s leadership in Canada—the world’s largest federally legal cannabis market.

The closing is subject to customary conditions, including HEXO shareholder and court approvals, with a June 2023 target. Management emphasizes that the acquisition will integrate HEXO’s brands and operations into Tilray’s efficient platform, potentially lifting pro-forma scale and distribution reach across Canada.

From a governance and share-count perspective, the stock-based consideration means dilution risk fades into the mix as Tilray optics the total equity structure post-close. Analysts will watch for the implied impact on EPS accretion or dilution, as the deal shifts Tilray’s cost structure and revenue mix toward HEXO’s brands and geographies.

Operating Highlights: Market positioning, cost discipline, and strategic leverage

Tilray maintains an emphasis on market leadership and efficiency. The company continues to claim the #1 cannabis market share in Canada, and with HEXO’s high-growth brands, Tilray anticipates stronger Canadian net sales and low-cost operations across geographies. The release highlights a pro-forma market share of 12.9% and broad distribution across Canadian geographies, signaling the potential for improved margins as scale compounds.

The management commentary stresses a focus on cost and operational efficiency alongside deliberate investments in brands that can leverage Tilray’s platform. The leadership reiterates a strategy to become the leading, most diversified cannabis lifestyle and CPG company, aiming to balance top-line growth with cash flow discipline.

Management Commentary: On growth, integration, and the road ahead

In his remarks, Tilray Chairman and CEO Irwin D. Simon framed the quarter as a continuation of a multi-quarter effort to grow revenue, optimize the platform, and move toward positive free cash flow on an accelerated timeline. He underscored progress across core markets and geographies while acknowledging market dynamics in Canada, Europe, and the U.S. He also highlighted the HEXO transaction as a meaningful step in strengthening Tilray’s global position and profitability.

Mark Attanasio, HEXO’s chairman, framed the combination as a continuation of a pragmatic cost-cutting and balance-sheet optimization plan. He signaled confidence that the combined brands would thrive under Tilray’s platform, with ongoing commitment to strengthening top- and bottom-line performance and value creation for shareholders.

Implications for peers and the sector: A more cash-efficient consolidation narrative

The Tilray / HEXO move is a reminder that cannabis sector players are increasingly positioning for scale through strategic combinations that amplify distribution and reduce unit costs. The emphasis on positive EBITDA and cash flow, even as implied stock-based consideration weighs on near-term earnings per share, could raise the bar for peers in Canada and Europe alike. That means: more attention to capital allocation, whether via bolt-on acquisitions financed with stock or debt, and a sharper focus on free cash flow generation as a near-term performance metric.

For sector peers, Tilray’s execution might set a tempo for M&A discussions and accelerate a broader re-pricing of growth-versus-margin narratives in cannabis and adjacent consumer health brands. If the HEXO deal unlocks meaningful cost savings and brand lift within Tilray’s existing platform, investors may look for similar combinations that promise revenue synergy and channel expansion without sacrificing balance-sheet discipline.

Bottom line: A quarter anchored in cash, a strategy anchored in scale

Tilray’s third-quarter results reinforce a theme that has persisted through the post-Aphria era: the company can generate positive EBITDA while inching toward free cash flow positivity, even as it pursues larger-scale expansion in Canada via HEXO. The corrected release, the emphasis on Adjusted EBITDA, and the planned HEXO acquisition together map a path toward greater market share, better cost leverage, and a more balanced capital structure—but with the caveat that the deal’s stock-based component introduces near-term dilution risk to EPS metrics and the EPS consensus across what remains a volatile sector.

For investors, Tilray’s narrative is less about a single earnings surprise and more about a disciplined journey toward profitability and scale. The market will likely treat the HEXO closing as a meaningful milestone—provided the stock markets and courts align—and will watch closely for any shifts in revenue forecast trajectory as Canada’s regulatory and competitive landscape evolves.